Scientists from Oxford University (UK) announced the successful completion of the first phase of clinical trials of potential vaccines against coronaviruses in humans. The study is published in the medical journal The Lancet.
AZD1222 the vaccine, created on the basis of chimpanzee adenovirus, was tested on 1077 the volunteers in April – may 2020.
The authors declare that all study participants after vaccination was observed, “humoral and cellular immune response”, accompanied by mild to moderate side effects. Most often, subjects reported pain at the site of inoculation, fever, chills, muscle and head aches, and malaise. Taking paracetamol weakened these symptoms, it is written in the results.
Overall, said the authors, the vaccine proved safety, so soon the scientists will begin the next stage of testing.
Special medications from COVID-19 does not exist now in this disease is only symptomatic treatment. The world health organization notedthat a number of medicines can contribute to improved well-being and relief of symptoms COVID-19, but there is no evidence that any drug to prevent or treat the disease.
The head of the European Agency of medicines Marco Kavaleri previously reported that a vaccine for the coronavirus in the best case will be ready next year. May 15, U.S. President Donald trump suggested that the coronavirus vaccine can be developed and tested by the end of 2020.
According to who, currently about 160 test vaccine against the coronavirus SARS-COV-2 / COVID-19 worldwide, more than 20 of them are in the final stages of testing.